Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Body fat composition impacts the hematologic toxicities and pharmacokinetics of doxorubicin in Asian breast cancer patients.

Wong AL, Seng KY, Ong EM, Wang LZ, Oscar H, Cordero MT, Copones R, Fan L, Tan SH, Goh BC, Lee SC.

Breast Cancer Res Treat. 2014 Feb;144(1):143-52. doi: 10.1007/s10549-014-2843-8. Epub 2014 Jan 31.

PMID:
24481679
2.

Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma.

Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshing NI, Lotem M, Brufman G, Gabizon A.

Cancer. 2000 Sep 1;89(5):1037-47.

PMID:
10964334
3.

Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients.

Lal S, Wong ZW, Jada SR, Xiang X, Chen Shu X, Ang PC, Figg WD, Lee EJ, Chowbay B.

Pharmacogenomics. 2007 Jun;8(6):567-75.

PMID:
17559346
4.

CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients.

Lal S, Sandanaraj E, Wong ZW, Ang PC, Wong NS, Lee EJ, Chowbay B.

Cancer Sci. 2008 Oct;99(10):2045-54. doi: 10.1111/j.1349-7006.2008.00903.x.

5.

Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG.

Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Féty R, de Bruijn E, Hempel G, Karlsson M, Tranchand B, Schrijvers AH, Twelves C, Beijnen JH, Schellens JH; EORTC-PAMM-NDDG..

Clin Pharmacokinet. 2007;46(12):1051-68.

PMID:
18027989
6.

Influence of the interval between the administration of doxorubicin and paclitaxel on the pharmacokinetics of these drugs in patients with locally advanced breast cancer.

Moreira A, Lobato R, Morais J, Silva S, Ribeiro J, Figueira A, Vale D, Sousa C, Araújo F, Fernandes A, Oliveira J, Passos-Coelho JL.

Cancer Chemother Pharmacol. 2001 Oct;48(4):333-7.

PMID:
11710635
7.

Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.

Toffoli G, Sorio R, Aita P, Crivellari D, Corona G, Bearz A, Robieux I, Colussi AM, Stocco F, Boiocchi M.

Clin Cancer Res. 2000 Jun;6(6):2279-87.

8.

Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.

Kontny NE, Würthwein G, Joachim B, Boddy AV, Krischke M, Fuhr U, Thompson PA, Jörger M, Schellens JH, Hempel G.

Cancer Chemother Pharmacol. 2013 Mar;71(3):749-63. doi: 10.1007/s00280-013-2069-1. Epub 2013 Jan 13.

PMID:
23314734
10.

PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients.

Hor SY, Lee SC, Wong CI, Lim YW, Lim RC, Wang LZ, Fan L, Guo JY, Lee HS, Goh BC, Tan T.

Pharmacogenomics J. 2008 Apr;8(2):139-46. Epub 2007 Sep 18.

PMID:
17876342
11.

Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study.

Freyer G, Tranchand B, Ligneau B, Ardiet C, Souquet PJ, Court-Fortune I, Riou R, Rebattu P, Boissel JP, Trillet-Lenoir V, Girard P.

Br J Clin Pharmacol. 2000 Oct;50(4):315-24.

12.

A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors.

Planting AS, Sonneveld P, van der Gaast A, Sparreboom A, van der Burg ME, Luyten GP, de Leeuw K, de Boer-Dennert M, Wissel PS, Jewell RC, Paul EM, Purvis NB Jr, Verweij J.

Cancer Chemother Pharmacol. 2005 Jan;55(1):91-9. Epub 2004 Jul 28.

PMID:
15565444
13.

Effects of intra-abdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intraperitoneal administration.

Jacquet P, Stuart OA, Chang D, Sugarbaker PH.

Anticancer Drugs. 1996 Jul;7(5):596-603.

PMID:
8862729
14.

Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.

Gabizon A, Shmeeda H, Barenholz Y.

Clin Pharmacokinet. 2003;42(5):419-36. Review.

PMID:
12739982
15.

Phase I and pharmacologic study of weekly doxorubicin and 1 h infusional paclitaxel in patients with advanced breast cancer.

Panday VR, ten Bokkel Huinink WW, Rosing H, Koopman FJ, Hillebrand MJ, Dubbelman RC, van Tellingen O, Schellens JH, Beijnen JH.

Anticancer Drugs. 1998 Sep;9(8):665-73.

PMID:
9823424
16.

Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents.

Chatelut E, White-Koning ML, Mathijssen RH, Puisset F, Baker SD, Sparreboom A.

Br J Cancer. 2012 Sep 25;107(7):1100-6. doi: 10.1038/bjc.2012.357. Epub 2012 Aug 28.

17.

Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.

Tranchand B, Catimel G, Lucas C, Sarkany M, Bastian G, Evene E, Guastalla JP, Négrier S, Rebattu P, Dumortier A, Foy M, Grossin F, Mazier B, Froudarakis M, Barbet N, Clavel M, Ardiet C.

Cancer Chemother Pharmacol. 1998;41(4):281-91.

PMID:
9488597
18.

Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass.

Barpe DR, Rosa DD, Froehlich PE.

Eur J Pharm Sci. 2010 Nov 20;41(3-4):458-63. doi: 10.1016/j.ejps.2010.07.015. Epub 2010 Aug 3.

PMID:
20688160
19.

A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.

Ganjoo KN, Cranmer LD, Butrynski JE, Rushing D, Adkins D, Okuno SH, Lorente G, Kroll S, Langmuir VK, Chawla SP.

Oncology. 2011;80(1-2):50-6. doi: 10.1159/000327739. Epub 2011 May 31.

PMID:
21625179
20.

Phase I clinical trial: pharmacokinetics of a novel anthracycline, DA-125 and metabolites. Single dose study.

Roh JK, Rha SY, Lee CI, Lee KH, Lee JJ, Shim HJ, Lee SD, Kim WB, Yang J, Kim SH, Lee MG.

Int J Clin Pharmacol Ther. 1998 Jun;36(6):312-9.

PMID:
9660038

Supplemental Content

Support Center